Foghorn Therapeutics Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
FHTX Nasdaq 2836 foghorntx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Foghorn Therapeutics Inc.

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May - May 12th, 2026 5:00 am
The Foghorn Therapeutics Inc. (NASDAQ:FHTX) First-Quarter Results Are Out And Analysts Have Published New Forecasts - May 11th, 2026 9:02 am
CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - May 7th, 2026 8:00 am
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates - May 7th, 2026 6:50 am
Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update - May 7th, 2026 5:00 am
Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Top Estimates - May 6th, 2026 3:25 pm
Foghorn Therapeutics Inc. (FHTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - May 6th, 2026 8:00 am
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Tops Revenue Estimates - May 5th, 2026 6:25 am
Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting - Apr 21st, 2026 2:05 pm
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting - Apr 9th, 2026 5:00 am
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength? - Apr 1st, 2026 1:52 am
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Beats Revenue Estimates - Mar 11th, 2026 3:55 pm
Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook - Mar 11th, 2026 2:09 pm
Verastem (VSTM) Reports Q4 Loss, Beats Revenue Estimates - Mar 4th, 2026 3:10 pm
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences - Feb 24th, 2026 5:00 am
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer - Feb 23rd, 2026 5:00 am
Foghorn Therapeutics CEO Talks Lilly-Partnered SMARCA2 Phase 1 and New Degrader Targets at Conference - Feb 13th, 2026 5:03 pm
Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit - Feb 3rd, 2026 5:00 am
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium - Jan 13th, 2026 2:05 pm
Is Foghorn Therapeutics (NASDAQ:FHTX) In A Good Position To Deliver On Growth Plans? - Jan 12th, 2026 4:53 am